Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists

Journal of Medicinal Chemistry

Volumn 59, Issue 23, 2016, Pages 10601-10618

  Chen, Xin ^a   McCorvy, John D ^b   Fischer, Matthew G ^a   Butler, Kyle V ^a   Shen, Yudao ^a   Roth, Bryan L ^b   Jin, Jian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL [1,1 BIPHENYL] 3 YL)PIPERAZINE; 2 ETHYL 5 [4 [4 (2 METHYLQUINOLIN 8 YL)PIPERAZIN 1 YL]BUTOXY]BENZO[D]THIAZOLE; 2 ISOPROPYL 5 [4 [4 (2 METHYLQUINOLIN 8 YL)PIPERAZIN 1 YL]BUTOXY]BENZO[D]THIAZOLE; 2 ISOPROPYL 5 [4 [4 (3 METHYLQUINOLIN 8 YL)PIPERAZIN 1 YL]BUTOXY]LBENZO[D]THIAZOLE; 5 CHLORO 7 [[4 (PYRIDIN 2 YL)PIPERAZIN 1 YL]METHYL]QUINOLIN 8 OL; 5 [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTOXY] 2 ETHYLBENZO[D]THIAZOLE; 5 [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTOXY] 2 METHYLBENZO[D]THIAZOLE; 5 [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTOXY] N METHYLBENZO[D]THIAZOL 2 AMINE; 5 [4 [4 (2,3 DICHLOROPHENYL)PIPERIDIN 1 YL]BUTOXY] 2 ISOPROPYLBENZO[D]THIAZOLE; 5 [4 [4 (2,3 DICHLOROPHENYL)PIPERIDIN 1 YL]BUTOXY] N METHYLBENZO[D]THIAZOL 2 AMINE; 5 [4 [4 (2,3 DIHYDROBENZO[B][1,4]DIOXIN 5 YL)PIPERAZIN 1 YL]BUTOXY] 2 ETHYLBENZO[D]THIAZOLE; 5 [4 [4 (2,3 DIHYDROBENZO[B][1,4]DIOXIN 5 YL)PIPERAZIN 1 YL]BUTOXY] 2 METHYLBENZO[D]THIAZOLE; 5 [4 [4 (2,3 DIHYDROBENZO[B][1,4]DIOXIN 5 YL)PIPERAZIN 1 YL]BUTOXY] N METHYLBENZO[D]THIAZOL 2 AMINE; 5 [4 [4 (2,3 DIHYDROBENZO[B][1,4]DIOXIN YL)PIPERAZIN 1 YL]BUTOXY] 2 ISOPROPYLBENZO[D]THIAZOLE; 5 [4 [4 (3,4 DIHYDRO 2H BENZO[B][1,4]OXAZIN 8 YL)PIPERAZIN 1 YL]BUTOXY] N METHYLBENZO[D]THIAZOL 2 AMINE; 6 [4 [4 (2,3 DICHLOROPHENYL)PIPERIDIN 1 YL]BUTOXY] 2 METHYLBENZO[D]THIAZOLE; 8 [4 [4 [(2 ETHYLBENZO[D]THIAZOL 5 YL)OXY]BUTYL]PIPERAZIN 1 YL] 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZINE; 8 [4 [4 [(2 ISOPROPYLBENZO[D]THIAZOL 5 YL)OXY]BUTYL]PIPERAZIN 1 YL] 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZINE; BENZOTHIAZOLE DERIVATIVE; BETA ARRESTIN 2; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; N METHYL 5 [4 [4 (2 METHYLQUINOLIN 8 YL)PIPERAZIN 1 YL]BUTOXY]BENZO[D]THIAZOL 2 AMINE; TERT BUTYL 4 (3 BROMO 2 METHYLPHENYL)PIPERAZINE 1 CARBOXYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ARIPIPRAZOLE; DRD2 PROTEIN, HUMAN; LIGAND;

ALKYLATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AGONISTS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; METABOLISM; SYNTHESIS;

ARIPIPRAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85003632910     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01208     Document Type: Article

References (52)

1. Hisahara, S.; Shimohama, S. Dopamine receptors and Parkinson’s Disease Int. J. Med. Chem. 2011, 2011, 403039 10.1155/2011/403039
2. Gray, J. A.; Roth, B. L. The pipeline and future of drug development in schizophrenia Mol. Psychiatry 2007, 12, 904-922 10.1038/sj.mp.4002062
3. Beaulieu, J. M.; Espinoza, S.; Gainetdinov, R. R. Dopamine receptors-IUPHAR Review 13 Br. J. Pharmacol. 2015, 172, 1-23 10.1111/bph.12906
4. Beaulieu, J. M.; Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011, 63, 182-217 10.1124/pr.110.002642
5. Noble, E. P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes Am. J. Med. Genet., Part B 2003, 116B, 103-125 10.1002/ajmg.b.10005
6. Fan, X. L.; Xu, M.; Hess, E. J. D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD Neurobiol. Dis. 2010, 37, 228-236 10.1016/j.nbd.2009.10.009
7. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 2004, 3, 353-359 10.1038/nrd1346
8. Davis, K. L.; Kahn, R. S.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization Am. J. Psychiatry 1991, 148, 1474-1486 10.1176/ajp.148.11.1474
9. Leucht, S.; Corves, C.; Arbter, D.; Engel, R. R.; Li, C. B.; Davis, J. M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 2009, 373, 31-41 10.1016/S0140-6736(08)61764-X
10. Caroff, S. N.; Hurford, I.; Lybrand, J.; Campbell, E. C. Movement disorders induced by antipsychotic drugs: implications of the CATIE Schizophrenia trial Neurologic Clinics 2011, 29, 127-148 10.1016/j.ncl.2010.10.002
11. Koster, L. S.; Carbon, M.; Correll, C. U. Emerging drugs for schizophrenia: an update Expert Opin. Emerging Drugs 2014, 19, 511-531 10.1517/14728214.2014.958148
12. Leo, R. J.; Del Regno, P. D. Atypical antipsychotic use in the treatment of psychosis in primary care Prim. Care Companion J. Clin. Psychiatry 2000, 2, 194-204 10.4088/PCC.v02n0601
13. Swainston Harrison, T.; Perry, C. M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder Drugs 2004, 64, 1715-1736 10.2165/00003495-200464150-00010
14. Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.; Roth, B. L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 2003, 28, 1400-1411 10.1038/sj.npp.1300203
15. Gopalakrishna, G.; Aggarwal, A.; Lauriello, J. Long-acting injectable aripiprazole: how might it fit in our tool box? Clin. Schizophr. Relat. Psychoses. 2013, 7, 87-92 10.3371/CSRP.GOAG.043013
16. Allen, J. A.; Yost, J. M.; Setola, V.; Chen, X.; Sassano, M. F.; Chen, M.; Peterson, S.; Yadav, P. N.; Huang, X. P.; Feng, B.; Jensen, N. H.; Che, X.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Caron, M. G.; Javitch, J. A.; Roth, B. L.; Jin, J. Discovery of beta-arrestin-biased dopamine D-2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 18488-18493 10.1073/pnas.1104807108
17. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 2007, 320, 1-13 10.1124/jpet.106.104463
18. Mailman, R. B. GPCR functional selectivity has therapeutic impact Trends Pharmacol. Sci. 2007, 28, 390-396 10.1016/j.tips.2007.06.002
19. Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. The Akt-GSK-3 signaling cascade in the actions of doparnine Trends Pharmacol. Sci. 2007, 28, 166-172 10.1016/j.tips.2007.02.006
20. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12, 205-216 10.1038/nrd3954
21. Chen, X.; Sassano, M. F.; Zheng, L. Y.; Setola, V.; Chen, M.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Roth, B. L.; Jin, J. Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D-2 receptor agonists J. Med. Chem. 2012, 55, 7141-7153 10.1021/jm300603y
22. Park, S. M.; Chen, M.; Schmerberg, C. M.; Dulman, R. S.; Rodriguiz, R. M.; Caron, M. G.; Jin, J.; Wetsel, W. C. Effects of beta-arrestin-biased dopamine D2 receptor ligands on Schizophrenia-like behavior in hypoglutamatergic mice Neuropsychopharmacology 2016, 41, 704-715 10.1038/npp.2015.196
23. Shonberg, J.; Herenbrink, C. K.; Lopez, L.; Christopoulos, A.; Scammells, P. J.; Capuano, B.; Lane, J. R. A Structure-activity analysis of biased agonism at the dopamine D2 receptor J. Med. Chem. 2013, 56, 9199-9221 10.1021/jm401318w
24. Hiller, C.; Kling, R. C.; Heinemann, F. W.; Meyer, K.; Hubner, H.; Gmeiner, P. Functionally selective dopamine D-2/D-3 receptor agonists comprising an enyne moiety J. Med. Chem. 2013, 56, 5130-5141 10.1021/jm400520c
25. Szabo, M.; Klein Herenbrink, C.; Christopoulos, A.; Lane, J. R.; Capuano, B. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D-2 receptor J. Med. Chem. 2014, 57, 4924-4939 10.1021/jm500457x
26. Moeller, D.; Kling, R. C.; Skultety, M.; Leuner, K.; Hubner, H.; Gmeiner, P. Functionally selective dopamine D-2, D-3 receptor partial agonists J. Med. Chem. 2014, 57, 4861-4875 10.1021/jm5004039
27. Free, R. B.; Chun, L. S.; Moritz, A. E.; Miller, B. N.; Doyle, T. B.; Conroy, J. L.; Padron, A.; Meade, J. A.; Xiao, J. B.; Hu, X.; Dulcey, A. E.; Han, Y.; Duan, L. H.; Titus, S.; Bryant-Genevier, M.; Barnaeva, E.; Ferrer, M.; Javitch, J. A.; Beuming, T.; Shi, L.; Southall, N. T.; Marugan, J. J.; Sibley, D. R. Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor Mol. Pharmacol. 2014, 86, 96-105 10.1124/mol.113.090563
28. Houslay, M. D. Arrestin times for developing antipsychotics and beta-blockers Sci. Signaling 2009, 2, pe22 10.1126/scisignal.266pe22
29. Mottola, D. M.; Kilts, J. D.; Lewis, M. M.; Connery, H. S.; Walker, Q. D.; Jones, S. R.; Booth, R. G.; Hyslop, D. K.; Piercey, M.; Wightman, R. M.; Lawler, C. P.; Nichols, D. E.; Mailman, R. B. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase J. Pharmacol. Exp. Ther. 2002, 301, 1166-1178 10.1124/jpet.301.3.1166
30. Kilts, J. D.; Connery, H. S.; Arrington, E. G.; Lewis, M. M.; Lawler, C. P.; Oxford, G. S.; O’Malley, K. L.; Todd, R. D.; Blake, B. L.; Nichols, D. E.; Mailman, R. B. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs J. Pharmacol. Exp. Ther. 2002, 301, 1179-1189 10.1124/jpet.301.3.1179
31. Masri, B.; Salahpour, A.; Didriksen, M.; Ghisi, V.; Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 13656-13661 10.1073/pnas.0803522105
32. Beaulieu, J. M.; Sotnikova, T. D.; Marion, S.; Lefkowitz, R. J.; Gainetdinov, R. R.; Caron, M. G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior Cell 2005, 122, 261-273 10.1016/j.cell.2005.05.012
33. Luttrell, L. M.; Ferguson, S. S.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, G. J.; Lin, F.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. J. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes Science 1999, 283, 655-661 10.1126/science.283.5402.655
34. Lefkowitz, R. J.; Shenoy, S. K. Transduction of receptor signals by beta-arrestins Science 2005, 308, 512-517 10.1126/science.1109237
35. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives J. Med. Chem. 1998, 41, 658-667 10.1021/jm940608g
36. Zhu, J. T.; Chen, Z. X.; Xie, H. B.; Li, S.; Wu, Y. M. A general and straightforward method for the synthesis of 2-trifluoromethylbenzothiazoles Org. Lett. 2010, 12, 2434-2436 10.1021/ol1006899
37. Weissman, S. A.; Zewge, D. Recent advances in ether dealkylation Tetrahedron 2005, 61, 7833-7863 10.1016/j.tet.2005.05.041
38. Shi, D. F.; Bradshaw, T. D.; Wrigley, S.; McCall, C. J.; Lelieveld, P.; Fichtner, I.; Stevens, M. F. G. Antitumor benzothiazoles 0.3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo J. Med. Chem. 1996, 39, 3375-3384 10.1021/jm9600959
39. Jordan, A. D.; Luo, C.; Reitz, A. B. Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide J. Org. Chem. 2003, 68, 8693-8696 10.1021/jo0349431
40. Kimple, A. J.; Soundararajan, M.; Hutsell, S. Q.; Roos, A. K.; Urban, D. J.; Setola, V.; Temple, B. R. S.; Roth, B. L.; Knapp, S.; Willard, F. S.; Siderovski, D. P. Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2) J. Biol. Chem. 2009, 284, 19402-19411 10.1074/jbc.M109.024711
41. Kroeze, W. K.; Sassano, M. F.; Huang, X. P.; Lansu, K.; McCorvy, J. D.; Giguere, P. M.; Sciaky, N.; Roth, B. L. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome Nat. Struct. Mol. Biol. 2015, 22, 362-369 10.1038/nsmb.3014
42. Tsuruta, K.; Frey, E. A.; Grewe, C. W.; Cote, T. E.; Eskay, R. L.; Kebabian, J. W. Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor Nature 1981, 292, 463-465 10.1038/292463a0
43. Yale, H. L. The trifluoromethyl group in medicinal chemistry J. Med. Pharm. Chem. 1959, 1, 121-133 10.1021/jm50003a001
44. Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G. New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D-2-receptor and serotonin 5-HT1A-receptor affinities Bioorg. Med. Chem. Lett. 2001, 11, 2345-2349 10.1016/S0960-894X(01)00425-5
45. Wagaw, S.; Rennels, R. A.; Buchwald, S. L. Palladium-catalyzed coupling of optically active amines with aryl bromides J. Am. Chem. Soc. 1997, 119, 8451-8458 10.1021/ja971583o
46. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12, 205-216 10.1038/nrd3954
47. Klein Herenbrink, C.; Sykes, D. A.; Donthamsetti, P.; Canals, M.; Coudrat, T.; Shonberg, J.; Scammells, P. J.; Capuano, B.; Sexton, P. M.; Charlton, S. J.; Javitch, J. A.; Christopoulos, A.; Lane, J. R. The role of kinetic context in apparent biased agonism at GPCRs Nat. Commun. 2016, 7, 10842 10.1038/ncomms10842
48. Klewe, I. V.; Nielsen, S. M.; Tarpo, L.; Urizar, E.; Dipace, C.; Javitch, J. A.; Gether, U.; Egebjerg, J.; Christensen, K. V. Recruitment of beta-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling Neuropharmacology 2008, 54, 1215-1222 10.1016/j.neuropharm.2008.03.015
49. Burris, K. D.; Molski, T. F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F. D.; Molinoff, P. B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J. Pharmacol. Exp. Ther. 2002, 302, 381-389 10.1124/jpet.102.033175
50. Winpenny, D.; Clark, M.; Cawkill, D. Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased opioid receptor agonists Br. J. Pharmacol. 2016, 173, 1393-1403 10.1111/bph.13441
51. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities J. Org. Chem. 1997, 62, 7512-7515 10.1021/jo971176v
52. Barnea, G.; Strapps, W.; Herrada, G.; Berman, Y.; Ong, J.; Kloss, B.; Axel, R.; Lee, K. J. The genetic design of signaling cascades to record receptor activation Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 64-69 10.1073/pnas.0710487105